Fluticasone propionate
- Generic Name
- Fluticasone propionate
- Brand Names
- Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance
- Drug Type
- Small Molecule
- Chemical Formula
- C25H31F3O5S
- CAS Number
- 80474-14-2
- Unique Ingredient Identifier
- O2GMZ0LF5W
- Background
Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.
- Indication
Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.
- Associated Conditions
- Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis
- Associated Therapies
- -
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 72
- Registration Number
- NCT06705387
- Locations
- 🇺🇸
Children's Hospital Colorado/University of Colorado School of Medicine, Aurora, Colorado, United States
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT05922761
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Susanna Naggie, MD
- Target Recruit Count
- 1407
- Registration Number
- NCT05736874
- Locations
- 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
- Conditions
- Interventions
- Drug: Squaric Acid Dibutyl EsterOther: Known patch test allergensDevice: MicroneedleDrug: DupilumabDevice: Suction blisteringDrug: AdalimumabProcedure: Skin punch biopsyDrug: UstekinumabDrug: GuselkumabDrug: CanakinumabDrug: SarilumabDrug: Triamcinolone AcetonideDrug: Betamethasone ValerateDrug: Fluticasone Propionate
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- John Harris
- Target Recruit Count
- 45
- Registration Number
- NCT05535738
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 75678
- Registration Number
- NCT05457855
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT05444543
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Andover Research Eye Institute
- Target Recruit Count
- 61
- Registration Number
- NCT05314621
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 924
- Registration Number
- NCT05158972
- Locations
- 🇭🇰
Asia Priority Healthcare, Kowloon, Hong Kong
🇲🇾Kempas Medical Center, Johor Bahru, Malaysia
🇲🇾University Malaya Medical Centre, Kuala Lumpur, Malaysia
FLuticasone in cOvid Treatment (FLOT)
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2021-09-23
- Target Recruit Count
- 500
- Registration Number
- NCT05054322
- Locations
- 🇻🇳
University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
ACTIV-6: COVID-19 Study of Repurposed Medications
- Conditions
- Interventions
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Susanna Naggie, MD
- Target Recruit Count
- 10956
- Registration Number
- NCT04885530
- Locations
- 🇺🇸
Emory Healthcare, Atlanta, Georgia, United States
🇺🇸Northwestern Univesity, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.